Mein Warenkorb

TPBG

TPBG Molekülinformation

Englischer NameTrophoblast glycoproteinAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel16Target-AliasTrophoblast glycoprotein,5T4 oncotrophoblast glycoprotein,5T4,TPBG,5T4 oncofetal antigen,M6P1,5T4 oncofetal trophoblast glycoprotein,Wnt-Activated Inhibitory Factor 1,WAIF1,5T4AG,5T4-AG
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameTrophoblast glycoprotein
Target-AliasTrophoblast glycoprotein,5T4 oncotrophoblast glycoprotein,5T4,TPBG,5T4 oncofetal antigen,M6P1,5T4 oncofetal trophoblast glycoprotein,Wnt-Activated Inhibitory Factor 1,WAIF1,5T4AG,5T4-AG
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel16
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

TPBG Molekülhintergrund

Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues.This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. TPBG is expressed by all types of trophoblasts as early as 9 weeks of development.

TPBG Molekülalias

TPBG,5T4,M6P1,5T4AG,WAIF1,5T4 oncofetal antigen,Trophoblast glycoprotein,5T4 oncofetal trophoblast glycoprotein

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
5T4 mAb - 01LeadMonoclonalHumanized MouseSolid TumorOvarian cancer,Lung cancer

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Naptumomab estafenatoxTTS-CD3; ABR-217620Phase 2 ClinicalActive Biotech AbBreast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Melanoma; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
ALG.APV-527ALG.APV 527; ADC-1016; ATOR-1016; ALG.APV-527; ALG-APV-527Phase 2 ClinicalAlligator Bioscience Ab, Aptevo Therapeutics IncNeoplasms; Solid tumours
Details
JK-06JK-06Phase 2 ClinicalXinlitai (Chengdu) Biological Technology Co LtdNeoplasms; Solid tumours
Details
TUB-030TUB-030Phase 2 ClinicalTubulis GmbHCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
ACR-246ACR246; ACR-246; ADC2154; ADC-2154Phase 2 ClinicalHangzhou Adcoris Biopharmacy Co LtdBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
IBR-854IBR854; IBR-854Phase 2 ClinicalImbioray (Hangzhou) Biomedicine Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Solid tumours
Details
SYD-1875SYD-1875Phase 1 ClinicalSynthon BvSolid tumours
Details
ASN-004ASN-004Phase 1 ClinicalAsana Biosciences LlcSolid tumours
Details
anti-5T4 CAR NK-cell therapy (Wuxi Peapole's Hospital/Hangzhou Yingbairui Biomedical Technology)Phase 1 ClinicalImbioray (Hangzhou) Biomedicine Co LtdSolid tumours
Details
Naptumomab estafenatox/DurvalumabNTX-352Phase 1 ClinicalNeotx Therapeutics LtdSolid tumours
Details
XB-010XB-010Phase 1 ClinicalExelixis IncBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
FTL-008.16FTL-008.16; FTL008.16Phase 1 ClinicalSound(Chengdu)Biopharmacauticals Co LtdSolid tumours
Details
CBA-1535CBA-1535Phase 1 ClinicalChiome Bioscience IncCarcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms
Details
Anti-5T4 CAR-raNK Cell TherapyPhase 1 ClinicalImbioray (Hangzhou) Biomedicine Co LtdSolid tumours
Details
Prostate cancer vaccine(inactivated viral)(University of Oxford)ClinicalUniversity Of OxfordProstatic Neoplasms
Details
68Ga-NOTA-H006ClinicalHuashan HospitalSolid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns